VC Fund Dossiers

Here's the deal: Abingworth got acquired by Carlyle in 2022 for $2 billion AUM, which means you're now dealing with a PE-backed entity, not an independent VC. This changes the dynamic entirely. The good news? They have serious biotech chops - 179 companies invested, 70 IPOs, 46 M&As, and their portfolio companies have secured 26 FDA approvals in the last 9 years alone. That's not marketing fluff, that's real execution. Founders consistently praise them as 'very engaged partners' with 'deep knowledge of the industry' and 'extensive networks' - the CEO testimonials are unusually glowing for biotech VCs. They've innovated with VIPEs (Venture Investments in Public Equities) for undervalued <$200M market cap biotechs, plus clinical co-development - so they're not just writing checks, they're creating new funding mechanisms. The Carlyle backing gives them serious firepower, but it also means they're playing with institutional money that has different return expectations than traditional VC funds.

Act met Barry Napier "over a decade ago" and made "the largest seed investment we possibly could" - this is a fund that bets big early and doubles down on winners. They explicitly say "We have never been the loudest venture firm" and "don't want to add to the noise of VCs making it about them." Strong exit track record including SilverCloud Health (acquired by Amwell), Decawave (acquired by Qorvo), and 34 total portfolio exits. Their strategy is clear: "find the best company builders at the earliest stages and continue to back them again and again." This isn't a spray-and-pray fund - they're conviction-driven, founder-focused, and have the dry powder (€140M Fund VI) to support you through multiple rounds.

AlbionVC is the grown-up in the room of UK venture - they've been doing this since 1996 and it shows in their disciplined, thesis-driven approach. Their partners project an aura of patience and take a genuinely long-term view, with reputation and consistency carrying more weight than flashy deals. Founders consistently praise Ed Lascelles specifically - Tony Pepper from Egress called him "equally important" to their success alongside the team and tech, while Quantexa's CEO said they've been privileged to work with Ed and AlbionVC from the beginning. They actually stick around - Quantexa went from first investment in 2017 to a $175m Series F at $2.6bn valuation in 2025, with AlbionVC participating in every round. The downside? They're not going to move fast on trendy deals, and if you want VC theater or ego stroking, look elsewhere.

Amadeus is one of the rare VCs that actually walks the walk on deep tech—they've been at it since 1997 when most funds were still figuring out what the internet was. As one founder, whose startup ContactEngine was acquired by NICE Systems, put it, landing investment from Amadeus meant securing one of "the best VCs in our space." Hermann Hauser's track record speaks for itself (he basically created ARM), and Anne Glover has built this into a proper institution. They are active investors who commonly take board seats and provide strategic advice, recruitment support, and introductions to international networks and corporate partners. The firm prides itself on being supportive yet measured, understanding when to step back and let the founders steer their company. The exit track record is genuinely impressive—multiple billion-dollar outcomes across different cycles. But here's the rub: they're extremely technical and will grill you hard on IP and defensibility. founders should be prepared for rigorous technical due diligence from Amadeus's experienced partners, many of whom bring a deep scientific background themselves.

Bayern Kapital operates as a co-investor alongside private investors, adhering to the pari-passu principle, and typically holds minority stakes. We invest according to the pari-passu principle. In the case of a financing round, this means that all parties involved are treated equally and must invest the same amount of capital as Bayern Kapital. This is both their strength and potential limitation - they're patient, government-backed capital that won't push for quick exits, but they require private lead investors to move. With 3 unicorns (IQM, Quantum Systems, EGYM) and strong exits like MorphoSys, they clearly pick winners, but their bureaucratic structure means slower decisions than pure private funds. Their 8-10 year investment horizons and €700M+ AUM make them ideal for deep tech that needs patient capital, but expect more process and committees than your typical VC.

Big Pi is the real deal in the Greek/diaspora space - they're not just tourist money but serious operators with legit exits under their belt (Accusonus to Meta for €70-100M). The team brings actual entrepreneurial chops: Marco built Upstream to €230M revenue, Nick was at Prime Ventures doing serious European deals, and Alex literally helped create the Python data science stack. They require portfolio companies to maintain substantial Greek operations, which is both a feature (cheap talent, government support) and potential bug (geographic constraint). Their "tech-first" mandate with IP requirements means they actually understand what defensible tech looks like, unlike funds that chase flashy B2C plays.

This is Spain's establishment VC - they're the corporate venture arm of CriteriaCaixa, which manages over €25 billion and is backed by la Caixa Foundation. They've been around since 2007 and have made 300+ investments, so they know what they're doing, but they're also exactly what you'd expect from a big Spanish bank's VC arm. The good news: they have serious capital staying power, they actually stick around for follow-on rounds, and they exit 20% more often than average. The reality check: they're not exactly known for being the fastest movers or most founder-friendly when it comes to terms. New CEO Jordi Ros comes from 20 years of traditional corporate finance, not startup-land.

CIC has genuinely unique deal flow through their exclusive Cambridge University relationship - this isn't marketing fluff, they literally have privileged access to the best IP coming out of one of the world's top research universities. Their track record speaks for itself: Bicycle Therapeutics IPO on NASDAQ, CMR Surgical unicorn, Gyroscope sold to Novartis for $1.5B, plus solid exits like Inivata ($390M) and PetMedix ($285M). Williamson brings serious credibility - 20 years US VC experience and co-chaired the UK government's university spinout review, so he knows the ecosystem inside out. Their Entrepreneur in Residence program is actually working - they're co-founding companies like Immutrin (just raised £65M from Frazier Life Sciences) by pairing seasoned operators with Cambridge academics. The downside? You're essentially betting on Cambridge staying relevant in deep tech, and they're very UK-focused if you want Silicon Valley-style growth.

Capricorn is the rare European VC that actually walks the walk on deep tech and sustainability—they've been doing cleantech since 2007, way before it was cool again. With 2 unicorns (Electric Hydrogen and Xanadu) in their portfolio and a track record spanning 26 years, they're not just another generalist fund pretending to understand hard science. Jos Peeters is a proper physics PhD who's been in the game for over three decades and built the European VC infrastructure we know today. The team genuinely gets technical due diligence, but here's the catch: they're very Belgian in their approach—methodical, relationship-focused, and not flashy. They invest mostly in Belgium (28 companies) and Netherlands (9 companies), so if you're not in their geographic sweet spot or willing to relocate there, you might find yourself on the outside looking in.

CDP is Italy's €4 billion sovereign wealth fund playing venture capitalist - which means you get the benefits of patient capital and government backing, but also all the bureaucracy that comes with it. They have an initial €1 billion to deploy and are making 40-50 investments per year, so they're not exactly selective. The real power here is Francesca Bria - she's the rare government appointee who actually gets technology and has street cred from transforming Barcelona's smart city approach. Under Resmini they grew from €230M to €4B AUM in 3 years, which is impressive scaling but raises questions about quality control. They're essentially the Italian government's attempt to bootstrap a venture ecosystem, so expect slower decision-making but also less pressure for quick exits since they're playing the long game for Italy's economic development.

Earlybird is one of Europe's genuine OG funds that's earned its stripes the hard way - they've been around since 1997 and have the exits to prove it. Their track record speaks volumes: early backer of UiPath (Europe's largest IPO ever), N26, and Aleph Alpha. What founders need to know is that this isn't just another check-writer - they genuinely get involved post-investment and have built serious operational expertise over 28 years. The recent restructuring shows they're not afraid to evolve and focus where they can add the most value. However, they're getting bigger and more institutionalized, which means longer decision cycles and more process than scrappy early-stage funds. They're also heavily Germanic in their approach - methodical, thorough, but sometimes slower to move than Silicon Valley-style funds.

Eurazeo is the French private equity heavyweight that's actually trying to be founder-friendly - and mostly succeeding. Many founders appreciate their authentic engagement without feeling displaced, with a partnership philosophy that resonates across stages. They've got serious scale (€39bn AUM) and real wins like Doctolib and Back Market, but here's the thing: some interview experiences reveal analysts who can be "borderline cocky" in a "not very pleasant" environment. The good news? 86% of employees would recommend working there, praising an "amazing culture" where "people are available to help." They're genuinely multi-stage (seed to Series C+) with deep sector expertise, but expect European-style formality and thorough due diligence processes that can drag on.